CD274 and non-small cell lung carcinoma: A series of groundbreaking trials—although not yet ASCO-recommended—have led to FDA approval for pembrolizumab and atezolizumab in naive NSCLC patients, irrespective of PD-L1 expression: combined with pemetrexed + platinum (nonsquamous histology)/(nab)paclitaxel + carboplatin (squamous histology) and with (nab)paclitaxel + carboplatin + bevacizumab (nonsquamous histology), respectively [20,25,26,27,28] (Table 2).